Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid.
- Author:
Eui Hyung LEE
1
;
Yeon Hee KIM
;
Sinyoung KIM
;
Song ee KIM
;
Soo Chan KIM
Author Information
- Publication Type:Original Article
- Keywords: BP180 protein; BP230 protein; Bullous pemphigoid; Enzyme-linked immunosorbent assay
- MeSH: Autoantibodies; Enzyme-Linked Immunosorbent Assay; Eosinophils; Epidermolysis Bullosa; Humans; Immunoglobulin G; Medical Records; Pemphigoid, Bullous; Pruritus; Retrospective Studies; Serologic Tests
- From:Annals of Dermatology 2012;24(1):45-55
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease associated with autoantibodies against BP180 and BP230. Enzyme-linked immunosorbent assay (ELISA) is a sensitive tool for the detection of immunoglobulin G (IgG) anti-BP180 and anti-BP230 autoantibodies. OBJECTIVE: The aim of this study was to evaluate the usefulness of ELISA for diagnosing and monitoring the disease activity of BP. METHODS: We evaluated serum IgG levels of anti-BP180 and anti-BP230 autoantibodies in 47 BP patients, 16 epidermolysis bullosa aquisita patients, and 15 healthy volunteers using ELISA. Through retrospective review of the medical records, the clinical characteristics of BP including disease activity, duration, pruritus severity and peripheral blood eosinophil counts were assessed. RESULTS: The sensitivity of BP180 ELISA was 97.9%, BP230 ELISA 72.3%, and a combination of the two was 100%. The specificity of BP180 ELISA was 90.3%, BP230 ELISA 100%, and a combination of the two was 90.3%. BP180 ELISA scores showed strong associations with disease activity, pruritus severity, peripheral blood eosinophil counts, and disease duration, whereas BP230 ELISA scores did not. CONCLUSION: BP180 and BP230 ELISAs are highly sensitive methods for the diagnosis of BP, and BP180 ELISA, in particular, is a sensitive tool for monitoring the disease activity of BP.
